(R)-9-(2-phosphonomethoxypropyl)guanine | 138247-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (R)-9-(2-phosphonomethoxypropyl)guanine
• 英文别名: Phosphonic acid, (((1R)-2-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-1-methylethoxy)methyl)-；[(2R)-1-(2-amino-6-oxo-1H-purin-9-yl)propan-2-yl]oxymethylphosphonic acid
• CAS: 138247-60-6
• 化学式: C₉H₁₄N₅O₅P
• 分子量: 303.214
• InChiKey: LDQMGQXMJIFSNJ-RXMQYKEDSA-N

物化性质

• 沸点：
  702.0±70.0 °C(Predicted)
• 密度：
  1.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  152
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (R)-9-(2-phosphonomethoxypropyl)guanine 、 N,N'-羰基二咪唑 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 [(2R)-1-(2-amino-6-oxo-1H-purin-9-yl)propan-2-yl]oxymethyl-imidazol-1-ylphosphinic acid
  参考文献：
  名称：

  [EN] GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS
  [FR] ANALOGUES DE GUANINE EN TANT QUE SUBSTRATS DE TÉLOMÉRASE ET AFFECTEURS DE LA LONGUEUR DE TÉLOMÈRES

  摘要：

  这项发明涉及用于抑制端粒延伸的化合物。更具体地说，该发明提供了一种通过端粒酶将核苷酸类似物嵌入端粒中，从而抑制端粒延伸的方法。这些化合物在治疗癌症和其他细胞增殖性疾病方面具有用途。

  公开号：

  WO2013095684A1
• 作为产物：
  描述：

  (S)-2-amino-6-chloro-9-<2-<(diisopropylphosphono)methoxy>propyl>purine 在 盐酸 、 三甲基溴硅烷 作用下， 以 乙腈 为溶剂， 反应 20.0h， 生成 (R)-9-(2-phosphonomethoxypropyl)guanine
  参考文献：
  名称：

  9- [2-（膦酰基甲氧基）乙基]鸟嘌呤的甲基衍生物的合成及抗病毒活性。

  摘要：

  已经合成了许多9- [2-（膦甲氧基）乙基]鸟嘌呤的甲基衍生物（PMEG，1），并在体外测试了其抗疱疹和抗人免疫缺陷病毒（HIV）的活性。在这些类似物中，（R）-2'-甲基-PMEG [[R] -3]和2'，2'-二甲基-PMEG（7）在XTT分析中显示出有效的抗HIV活性，EC50值为1.0和分别为2.6 microM。发现相应的（S）-2'-甲基-PMEG [（S）-3]对HIV的效力较低。另外，制备9- [3-羟基-2-（膦甲氧基）丙基]鸟嘌呤的（R）和（S）对映异构体（HPMPG，8）用于比较生物学活性，并显示出对疱疹病毒的活性和等效性。 ，但对HIV无效。

  DOI：

  10.1021/jm00094a005

文献信息

• Synthesis of Enantiomeric N-(2-Phosphonomethoxypropyl) Derivatives of Purine and Pyrimidine Bases. II. The Synthon Approach
  作者：Antonín Holý、Hana Dvořáková、Milena Masojídková

  DOI：10.1135/cccc19951390

  日期：——

  Another approach to (R)- and (S)-N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases (PMP derivatives) I and II is described, consisting in alkylation of the heterocyclic base with (R)- and (S)-2-[bis(2-propyl)phosphonylmethoxy]propyl p-toluenesulfonates (X and XVIII) followed by transsilylation of the intermediary N-[2-bis(2-propyl)phosphonylmethoxypropyl] derivatives XI and XIX. The key intermediates X and XVIII were obtained from 1-benzyloxypropanols VI and XIV by two routes: (i) condensation with bis(2-propyl) p-toluenesulfonyloxymethylphosphonate (XIII), hydrogenolysis of the obtained 1-benzyloxy-2-bis(2-propyl)phosphonylmethoxypropanes VIII and XVI over Pd/C to 2-bis(2-propyl)phosphonylmethoxypropanols IX and XVII and tosylation of the latter or (ii) chloromethylation of compounds VI and XIV and subsequent reaction of the chloromethyl ethers VII and XV with tris(2-propyl) phosphite and further processing of the benzyl ethers VIII and XVI analogous to the enantiomeric propanols IX and XVII. This approach was used for the synthesis of derivatives of adenine (Ia, IIa), 2,6-diaminopurine (Ib, IIb) and 3-deazaadenine (Ic, IIc). Their guanine counterparts Ie and IIe were prepared by hydrolysis of 2-amino-6-chloropurine intermediates XId and XIXd. 6-Chloropurine was converted into diester XIi by reaction with tosylate X, which on reaction with thiourea and subsequent ester cleavage afforded the 6-thiopurine derivative Ij. Analogously, 2-amino-6-chloropurine derivative XId reacted with thiourea to give 9-(R)-(2-phosphonomethoxypropyl)-2-thioguanine (If), or with dimethylamine under formation of (2-phosphonomethoxypropyl)-2-amino-6-dimethylaminopurine (Ig). Hydrogenolysis of compound XId gave 9-(R)-(2-phosphonomethoxypropyl)-2-aminopurine (Ik). Hydrolytic deamination of adenine derivatives Ia and IIa led to enantiomeric (2-phosphonomethoxypropyl)hypoxanthines Ih and IIh.

  描述了另一种合成嘧啶和嘌呤碱基的(R)和(S)-N-(2-磷酸甲氧丙基)衍生物（PMP衍生物）I和II的方法，包括用(R)和(S)-2-[双(2-丙基)磷酸甲氧基]丙基p-甲苯磺酸酯(X和XVIII)烷基化杂环碱基，然后通过中间体N-[2-双(2-丙基)磷酸甲氧基丙基]衍生物XI和XIX的转硅基化来制备。关键的中间体X和XVIII是从1-苄氧基丙醇VI和XIV通过两种途径获得的：（i）与双(2-丙基)p-甲苯磺酰氧甲基磷酸酯(XIII)缩合，氢解得到1-苄氧基-2-双(2-丙基)磷酸甲氧基丙烷VIII和XVI，再经Pd/C转化为2-双(2-丙基)磷酸甲氧基丙醇IX和XVII，然后对后者进行对甲苯磺酸基化或（ii）氯甲基化化合物VI和XIV，随后氯甲醚VII和XV与三(2-丙基)磷酸酯反应，进一步处理苄醚VIII和XVI类似对映体丙醇IX和XVII。这种方法被用于合成腺嘌呤(Ia，IIa)、2,6-二氨基嘌呤(Ib，IIb)和3-去氧腺嘌呤(Ic，IIc)的衍生物。它们的鸟嘌呤对应物Ie和IIe通过水解2-氨基-6-氯嘌呤中间体XId和XIXd制备。6-氯嘌呤通过与甲苯磺酸酯X反应转化为二酯XIi，再与硫脲反应并进行酯解得到6-硫嘌呤衍生物Ij。类似地，2-氨基-6-氯嘌呤衍生物XId与硫脲反应得到9-(R)-(2-磷酸甲氧丙基)-2-硫鸟嘌呤(If)，或与二甲胺反应形成(2-磷酸甲氧丙基)-2-氨基-6-二甲胺嘌呤(Ig)。化合物XId的氢解得到9-(R)-(2-磷酸甲氧丙基)-2-氨基嘌呤(Ik)。腺嘌呤衍生物Ia和IIa的水解脱氨基反应得到对映的(2-磷酸甲氧丙基)次黄嘌呤Ih和IIh。
• Synthesis of Enantiomeric N-(2-Phosphonomethoxypropyl) Derivatives of Purine and Pyrimidine Bases. I. The Stepwise Approach
  作者：Antonín Holý、Milena Masojídková

  DOI：10.1135/cccc19951196

  日期：——

  The (R)- and (S)-N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases (PMP derivatives) exhibit very high activity against retroviruses. This paper describes the synthesis of enantiomeric 9-(2-phosphonomethoxypropyl)adenines (I and XXVII), 9-(2-phosphonomethoxypropyl)-2,6-diaminopurines (II and XXXI), 9-(2-phosphonomethoxypropyl)guanines (III and XXIX) and 1-(R)-(2-phosphonomethoxypropyl)cytosine (XIX) by alkylation of N-protected N-(2-hydroxypropyl) derivatives of the corresponding bases with bis(2-propyl) p-toluenesulfonyloxymethylphosphonate (X), followed by stepwise N- and O-deprotection of the intermediates. The key intermediates, N-(2-hydroxypropyl) derivatives IX and XXV, were obtained by alkylation of the appropriate heterocyclic base with (R)- or (S)-2-(2-tetrahydropyranyloxy)propyl p-toluenesulfonate (VII or XXIII) and acid hydrolysis of the resulting N-[2-(2-tetrahydropyranyloxy)propyl] derivatives VIII and XXII. The chiral synthons were prepared by tosylation of (R)- or (S)-2-(2-tetrahydropyranyloxy)propanol (VI or XXI) available by reduction of enantiomeric alkyl 2-O-tetrahydropyranyllactates V and XXI with sodium bis(2-methoxyethoxy)aluminum hydride. This approach was used for the synthesis of cytosine, adenine and 2,6-diaminopurine derivatives, while compounds derived from guanine were prepared by hydrolysis of 2-amino-6-chloropurine intermediates. Cytosine derivative IXe was also synthesized by alkylation of 4-methoxy-2-pyrimidone followed by ammonolysis of the intermediate IXf.

  (R)和(S)-N-(2-磷酸甲氧基丙基)嘌呤和嘧啶碱（PMP衍生物）对逆转录病毒表现出非常高的活性。本文描述了对映异构体9-(2-磷酸甲氧基丙基)腺嘌呤（I和XXVII）、9-(2-磷酸甲氧基丙基)-2,6-二氨基嘌呤（II和XXXI）、9-(2-磷酸甲氧基丙基)鸟嘌呤（III和XXIX）和1-(R)-(2-磷酸甲氧基丙基)胞嘧啶（XIX）的合成，方法是用双(2-丙基) p-甲苯磺酰氧甲基膦酸酯（X）烷基化对应碱的N保护N-(2-羟基丙基)衍生物，然后逐步去保护中间体的N和O。关键中间体，N-(2-羟基丙基)衍生物IX和XXV，是通过将适当的杂环碱与(R)-或(S)-2-(2-四氢吡喃氧基)丙基 p-甲苯磺酸酯（VII或XXIII）烷基化，并酸水解得到的N-[2-(2-四氢吡喃氧基)丙基]衍生物VIII和XXII。手性合成物是通过对(R)-或(S)-2-(2-四氢吡喃氧基)丙醇（VI或XXI）进行对烯基化制备的，这些化合物可通过还原对映异构烷基2-O-四氢吡喃基乳酸酯V和XXI与双(2-甲氧基乙氧基)铝氢化钠反应得到。这种方法用于合成胞嘧啶、腺嘌呤和2,6-二氨基嘌呤衍生物，而从鸟嘌呤衍生物制备的化合物则是通过2-氨基-6-氯嘌呤中间体的水解制备的。胞嘧啶衍生物IXe也是通过对4-甲氧基-2-嘧啶酮的烷基化后接着中间体IXf的氨解合成的。
• Inhibition of human purine nucleoside phosphorylase by tenofovir phosphate congeners
  作者：Ivan Votruba、Jana Trýznová、Petra Břehová、Eva Tloušťová、Květoslava Horská、Jindřich Fanfrlík、Ondřej Přenosil、Antonín Holý

  DOI：10.1135/cccc2010094

  日期：——

  The structure-activity study on the phosphates of phosphonomethoxypropyl derivatives of purine bases interacting with human purine nucleoside phosphorylase has shown that the most efficient inhibitors of the enzyme are (R)- and (S)-PMPGp with K_i ~ 1.9 × 10^–8 and/or 2.2 × 10^–8 mol/l. The kinetic experiments have proven, with the exception of both enantiomers of PMP-8-BrDAPp, strictly competitive character of inhibition for all ANP monophosphates tested. Bromine derivatives exhibited uncompetitive and mixed type of inhibition as well. These results were confirmed by docking studies. The substitution of purine moiety with the bromine at the position 8 lead to an allosteric binding of these compounds toward the enzyme.

  磷酸基嘧啶碱的磷酸甲氧基丙基衍生物与人类嘌呤核苷酸磷酸酰化酶相互作用的结构-活性研究表明，酶的最有效抑制剂是（R）-和（S）-PMPGp，其Ki约为1.9×10^-8和/或2.2×10^-8mol/l。动力学实验证明，除了PMP-8-BrDAPp的两个对映异构体外，所有测试的ANP单磷酸都具有严格的竞争性抑制特性。溴衍生物也表现出非竞争性和混合型抑制。这些结果得到了对接研究的证实。在位置8上用溴代替嘌呤基团导致这些化合物对酶的异构结合。
• [EN] ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS<br/>[FR] ANALOGUES DE NUCLEOTIDES ENANTIOMERES ANTIRETROVIRAUX
  申请人：INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC

  公开号：WO1994003467A2

  公开（公告）日：1994-02-17

  (EN) Resolved enantiomers of formulae (IA) and (IB) wherein B is a purine or pyrimidine base or aza and/or deaza analogs thereof are useful in antiviral pharmaceutical compositions to treat retroviral infections.(FR) Des énantiomères dédoublés des formules (IA) et (IB) où B est une base purique ou pyrimidique, ou bien des analogues aza et/ou désaza de ceux-ci sont utiles dans des compositions pharmaceutiques antivirales pour traiter des infections rétrovirales.

  (中文) 公式（IA）和（IB）的旋光异构体，其中B是嘌呤或嘧啶碱基或其氮杂环和/或去氮杂环衍生物，可用于抗病毒药物组合物中，用于治疗逆转录病毒感染。
• Phosphonate Compounds
  申请人：Hostetler Karl Y.

  公开号：US20120058975A1

  公开（公告）日：2012-03-08

  The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

  本发明涉及膦酸盐化合物、包含它们的组合物、获取它们的过程以及它们用于治疗多种医学疾病的用途，例如骨质疏松和其他骨代谢紊乱、癌症、病毒感染等。